Showing results (31-40 of 102) with videos related to

Sort By:
Pageof 11
Scientific Reports|March 8, 2018
Neutrophil-to-lymphocyte Ratio (NLR) as a predictor for recurrence in patients with stage III melanomaJunjie Ma, James Kuzman, Abhijit Ray, et al.
Endocrinology|May 16, 2023
Cancer Cell-Extrinsic Roles for the Androgen Receptor in Prostate CancerAndrew W Hahn, Bilal A Siddiqui, Javier Leo, et al.
The Oncologist|November 18, 2024
Leptin levels are associated with coronary artery calcification in patients with advanced prostate cancerEfstratios Koutroumpakis, Neha Venkatesh, Ana Aparicio, et al.
The Oncologist|February 12, 2020
A Phase I Study of Alpha-1,3-Galactosyltransferase-Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell CarcinomaAndrew W Hahn, Charles Drake, Samuel R Denmeade, et al.
European Urology Oncology|October 8, 2019
First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysisAndrew W Hahn, Zachary Klaassen, Neeraj Agarwal, et al.
Cardio-Oncology (London, England)|September 13, 2023
Cardiometabolic healthcare for men with prostate cancer: an MD Anderson Cancer Center experienceAndrew W Hahn, Whittney Thoman, Efstratios Koutroumpakis, et al.
Investigational New Drugs|March 26, 2021
Pembrolizumab for advanced penile cancer: a case series from a phase II basket trialAndrew W Hahn, Jad Chahoud, Matthew T Campbell, et al.
Oncotarget|April 22, 2017
Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implicationsAndrew W Hahn, David M Gill, Benjamin Maughan, et al.
The Oncologist|March 13, 2024
Efficacy, Safety, and Tolerability of Tivozanib in Heavily Pretreated Patients With Advanced Clear Cell Renal Cell CarcinomaAndrew C Johns, Matthew T Campbell, Mamie Gao, et al.
Urologic Oncology|February 17, 2019
Time from definitive therapy to onset of metastatic disease predicts outcomes in men with metastatic hormone sensitive prostate cancerAndrew W Hahn, David D Stenehjem, Anitha B Alex, et al.
Pageof 11